|

Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT

RECRUITINGSponsored by Fudan University
Actively Recruiting
SponsorFudan University
Started2026-05-06
Est. completion2028-05-01
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted

Summary

The goal of this observational study is to evaluate the feasibility and effectiveness of using non-contrast chest computed tomography scans for opportunistic breast cancer screening, and to further compare its diagnostic performance with conventional imaging modalities, including mammography and/or breast magnetic resonance imaging.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

1. Female patients who have undergone non-contrast chest CT examination;
2. Participants included in the comparative analysis must have undergone at least one comparator imaging modality (mammography and/or breast MRI);
3. If a breast lesion is detected, it must be confirmed by pathology or clinical follow-up at least 12 months;
4. No prior systemic or local therapy before imaging examinations;
5. Imaging data are complete and of sufficient quality for analysis.

Exclusion Criteria:

1. History of other malignancies with potential impact on breast imaging interpretation;
2. Participants with suspected malignant breast lesions but no confirmation;
3. Prior radiotherapy, chemotherapy, or immunotherapy before imaging examinations;
4. Imaging data that are incomplete, of poor quality, or contain significant artifacts preventing reliable analysis;
5. Time interval between non-contrast chest CT and comparator imaging modalities exceeding three months, or with clinical events occurring between examinations that may alter lesion status.

Conditions2

Breast CancerCancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.